Valeant Pharmaceuticals International (VRX) :The total money flow, which is calculated as the dollar value of composite uptick minus downtick trades was negative ($13.91 million) and the uptick to downtick ratio was 0.89. The transaction value on upticks was $116.55 million and on downticks, the transaction value was $130.45 million. In block trades, the transaction value of inflow done during uptick was $12.07 million. The transaction value of block trades during downticks was $8.8 million. The uptick to downtick block trade ratio was 1.37. The money flow was negative ($3.27 million), indicating the traders were booking profit on the price strength. Valeant Pharmaceuticals International (VRX) rose $0.61 at $23.47, during intraday Monday , a rise of 2.67% over the previous days close.
Valeant Pharmaceuticals International, Inc. has dropped 29.51% during the last 3-month period . Year-to-Date the stock performance stands at -76.88%. Shares of Valeant Pharmaceuticals International, Inc. rose by 1.78% in the last five trading days and 4.82% for the last 4 weeks. In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the Director of Valeant Pharmaceuticals International, Inc., Ross Thomas W. Sr., had purchased 4,000 shares in a transaction dated on June 13, 2016. The transaction was executed at $24.4 per share with total amount equaling $97,600.
Valeant Pharmaceuticals International (NYSE:VRX): stock turned positive on Monday. Though the stock opened at $22.77, the bulls momentum made the stock top out at $24.25 level for the day. The stock recorded a low of $22.7 and closed the trading day at $23.5, in the green by 2.80%. The total traded volume for the day was 23,979,680. The stock had closed at $22.86 in the previous days trading.
Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Companys developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Companys Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.